[{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Mitsubishi Tanabe Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eli Lilly \/ Mitsubishi Tanabe Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Mitsubishi Tanabe Pharma"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Enobosarm","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Veru \/ Not Applicable"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Azelaprag","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"BioAge Labs \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"BioAge Labs \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Sofinnova Investments","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","year":"2024","type":"Series D Financing","leadProduct":"Azelaprag","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"BioAge Labs","amount2":0.17000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.17000000000000001,"dosageForm":"","sponsorNew":"BioAge Labs \/ Sofinnova Investments","highestDevelopmentStatusID":"4","companyTruncated":"BioAge Labs \/ Sofinnova Investments"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Sleep","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Bremelanotide Acetate","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Palatin Technologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Palatin Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Bremelanotide Acetate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Palatin Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Azelaprag","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BioAge Labs \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"BioAge Labs \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Bremelanotide Acetate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Palatin Technologies \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Palatin Technologies \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Tirzepatide

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Vyleesi (bremelanotide) is a melanocortin receptor 4 agonist (MCR4), which is being evaluated in combination with tirzepatide for the treatment of obesity.

                          Brand Name : Vyleesi

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          August 22, 2024

                          Lead Product(s) : Bremelanotide Acetate,Tirzepatide

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Zepbound (tirzepatide) injection is an obesity treatment targeting GIP and GLP-1 hormone receptors. Currently being studied for adults with heart failure with preserved ejection fraction and obesity.

                          Brand Name : Zepbound

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          August 01, 2024

                          Lead Product(s) : Tirzepatide

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : BGE-105 (azelaprag), an oral apelin receptor agonist in combination with Lilly’s Zepbound (tirzepatide) and other incretins for the treatment of obesity.

                          Brand Name : BGE-105

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 29, 2024

                          Lead Product(s) : Azelaprag,Tirzepatide

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Zepbound (tirzepatide) injection is a first obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.

                          Brand Name : Zepbound

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          July 19, 2024

                          Lead Product(s) : Tirzepatide

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Vyleesi (bremelanotide) is a melanocortin receptor 4 agonist (MCR4), which is being evaluated in combination with tirzepatide for the treatment of obesity.

                          Brand Name : Vyleesi

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          June 12, 2024

                          Lead Product(s) : Bremelanotide Acetate,Tirzepatide

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : PT-141 (bremelanotide) is a melanocortin receptor 4 agonist (MCR4), which is being evaluated in combination with tirzepatide for the treatment of obesity.

                          Brand Name : PT-141

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          May 02, 2024

                          Lead Product(s) : Bremelanotide Acetate,Tirzepatide

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Zepbound (tirzepatide) injection acts by activating both, glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 hormone receptors. It is being evaluated for OSA & obesity.

                          Brand Name : Zepbound

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          April 17, 2024

                          Lead Product(s) : Tirzepatide

                          Therapeutic Area : Sleep

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Funding will support Phase II development of BioAge’s BGE-105 (azelaprag), an oral apelin receptor agonist in combination with Lilly’s Zepbound for obesity treatment.

                          Brand Name : BGE-105

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          February 13, 2024

                          Lead Product(s) : Azelaprag,Tirzepatide

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Preclinical

                          Sponsor : Sofinnova Investments

                          Deal Size : $170.0 million

                          Deal Type : Series D Financing

                          blank

                          09

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Zepbound™ (tirzepatide) injection is the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.

                          Brand Name : Zepbound

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          November 08, 2023

                          Lead Product(s) : Tirzepatide

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : As part of the collaboration, Lilly will supply tirzepatide and Chorus will provide clinical trial design and execution expertise. BioAge retains worldwide exclusive rights to develop and commercialize BGE-105 (azelaprag) for all indications.

                          Brand Name : BGE-105

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 26, 2023

                          Lead Product(s) : Azelaprag,Tirzepatide

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Preclinical

                          Sponsor : Eli Lilly

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank